Terence Flynn
Stock Analyst at Morgan Stanley
(4.50)
# 290
Out of 5,147 analysts
237
Total ratings
63.41%
Success rate
15.68%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Overweight | $1,290 → $1,313 | $1,051.99 | +24.81% | 24 | Feb 5, 2026 | |
| ABBV AbbVie | Maintains: Overweight | $269 → $270 | $232.08 | +16.34% | 20 | Feb 5, 2026 | |
| AMGN Amgen | Maintains: Equal-Weight | $304 → $309 | $388.16 | -20.39% | 12 | Feb 4, 2026 | |
| JNJ Johnson & Johnson | Upgrades: Overweight | $200 → $262 | $248.43 | +5.46% | 28 | Jan 28, 2026 | |
| RCUS Arcus Biosciences | Downgrades: Equal-Weight | $23 → $20 | $20.37 | -1.82% | 9 | Jan 8, 2026 | |
| NRIX Nurix Therapeutics | Upgrades: Overweight | $15 → $36 | $15.97 | +125.42% | 7 | Jan 8, 2026 | |
| ALMS Alumis | Maintains: Overweight | $22 → $33 | $29.69 | +11.15% | 3 | Jan 7, 2026 | |
| BHVN Biohaven | Maintains: Overweight | $26 → $21 | $11.52 | +82.29% | 5 | Jan 6, 2026 | |
| PFE Pfizer | Maintains: Equal-Weight | $28 → $27 | $27.65 | -2.35% | 21 | Dec 17, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $36 → $37 | $62.37 | -40.68% | 12 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $102 | $123.82 | -17.62% | 20 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $62.98 | +98.48% | 2 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $516 → $564 | $496.83 | +13.52% | 3 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $9 | $7.29 | +23.46% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $54 | $46.21 | +16.86% | 13 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $133 → $131 | $110.23 | +18.84% | 5 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $328 → $435 | $503.90 | -13.67% | 11 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $13.27 | -17.11% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $60.14 | -46.79% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $13.78 | -20.17% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.70 | +196.30% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $191.82 | +127.30% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $332.92 | - | 2 | Oct 2, 2017 |
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $1,290 → $1,313
Current: $1,051.99
Upside: +24.81%
AbbVie
Feb 5, 2026
Maintains: Overweight
Price Target: $269 → $270
Current: $232.08
Upside: +16.34%
Amgen
Feb 4, 2026
Maintains: Equal-Weight
Price Target: $304 → $309
Current: $388.16
Upside: -20.39%
Johnson & Johnson
Jan 28, 2026
Upgrades: Overweight
Price Target: $200 → $262
Current: $248.43
Upside: +5.46%
Arcus Biosciences
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $23 → $20
Current: $20.37
Upside: -1.82%
Nurix Therapeutics
Jan 8, 2026
Upgrades: Overweight
Price Target: $15 → $36
Current: $15.97
Upside: +125.42%
Alumis
Jan 7, 2026
Maintains: Overweight
Price Target: $22 → $33
Current: $29.69
Upside: +11.15%
Biohaven
Jan 6, 2026
Maintains: Overweight
Price Target: $26 → $21
Current: $11.52
Upside: +82.29%
Pfizer
Dec 17, 2025
Maintains: Equal-Weight
Price Target: $28 → $27
Current: $27.65
Upside: -2.35%
Bristol-Myers Squibb Company
Dec 12, 2025
Maintains: Underweight
Price Target: $36 → $37
Current: $62.37
Upside: -40.68%
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $100 → $102
Current: $123.82
Upside: -17.62%
Dec 12, 2025
Maintains: Overweight
Price Target: $120 → $125
Current: $62.98
Upside: +98.48%
Dec 5, 2025
Maintains: Overweight
Price Target: $516 → $564
Current: $496.83
Upside: +13.52%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $10 → $9
Current: $7.29
Upside: +23.46%
Oct 10, 2025
Maintains: Overweight
Price Target: $55 → $54
Current: $46.21
Upside: +16.86%
Oct 10, 2025
Maintains: Overweight
Price Target: $133 → $131
Current: $110.23
Upside: +18.84%
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $328 → $435
Current: $503.90
Upside: -13.67%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $13.27
Upside: -17.11%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $60.14
Upside: -46.79%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $13.78
Upside: -20.17%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.70
Upside: +196.30%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $191.82
Upside: +127.30%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $332.92
Upside: -